Sat Kartar Shopping Limited specializes in Ayurveda-based healthcare, providing natural wellness solutions for both therapeutic and lifestyle needs. The IPO allotment for Sat Kartar is likely to be finalized today, January 15, 2025.
The Sat Kartar Shopping IPO is a book-built issue with a total size of ₹33.80 crores, consisting entirely of a fresh issue of 41.73 lakh shares. The subscription period for the IPO runs from January 10, 2025, to January 14, 2025. The allotment of shares is scheduled to be finalized on Wednesday, January 15, 2025, with the tentative listing date set for Friday, January 17, 2025, on the NSE SME platform. The IPO is priced within a range of ₹77 to ₹81 per share, and the minimum application size is 1,600 shares. Retail investors are required to make a minimum investment of ₹1,29,600, while high net-worth individuals (HNI) must invest at least ₹2,59,200, equivalent to 2 lots or 3,200 shares.
The net proceeds from the Fresh Issue will be strategically utilized to support the company’s growth initiatives and operational enhancements. A sum of ₹5 crores is earmarked for potential acquisitions, both domestic and international, to expand the business footprint. Additionally, ₹11 crores will be invested in marketing and advertising efforts to enhance brand visibility and customer engagement. To bolster infrastructure, ₹8 crores will be directed toward capital expenditures, while ₹5 crores will be dedicated to advancing technology development. The remaining funds will be used for general corporate purposes, ensuring financial flexibility and sustained growth.
(January 14, 2025, End of the Day)
The Sat Kartar Shopping IPO saw a subscription of 332.78 times on January 14, 2025. The retail category was subscribed 250.35 times, non-institutional investors (NII) was subscribed 808.3 times, and qualified institutional buyers (QIB) was subscribed 124.75 times.
GMP Details: As per Business Standard, the Grey Market Premium (GMP) for the Sat Kartar Shopping SME IPO stands at ₹60. With a price band of ₹81.00, the estimated listing price for the IPO is ₹141 (calculated as the cap price plus today’s GMP), with a gain of 74.07%.
Note: The Grey Market Premium (GMP) is not an official price and is based on market speculation.
Founded in June 2012, Sat Kartar Shopping Limited is a pioneer in Ayurveda-based healthcare, delivering natural wellness solutions that cater to both therapeutic and lifestyle needs. With a focus on healthier living, the company offers a wide range of holistic products rooted in the rich traditions of Ayurveda, seamlessly blended with modern consumer demands.
Sat Kartar Shopping Limited distributes its products through various channels, including its official website, leading e-commerce platforms, television marketing campaigns, and targeted digital advertising on Google and Meta. This multi-channel approach ensures accessibility and convenience for its growing customer base.
Beyond its Ayurvedic product range, the company is committed to customer satisfaction by offering tailored wellness solutions and fostering awareness about the advantages of holistic health. By merging tradition with innovation, Sat Kartar Shopping Limited continues to empower individuals on their journey toward improved well-being.
Disclaimer: The GMP (Grey Market Premium) price is unauthenticated market-related news and has no discernible basis. The same quoted above is as per news that appeared in the media report and is for information purposes only. The investor shall do their own study/research before using the same for taking any decision to invest. We neither engage in, trade or deal in the grey market nor do we recommend or endorse trading in the grey market.
Disclaimer: Investing in SME IPOs involves a high degree of risk. Such investments may be suitable only for investors with a high-risk tolerance and the ability to bear potential losses. Perform thorough due diligence and consult a financial advisor before investing. Invest wisely and at your own discretion.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here